Jacob Pfaller v. Mark Amonette

55 F.4th 436
Court of Appeals for the Fourth Circuit·Decided December 15, 2022·No. 21-1555·Published·Cited by 55 cases

Opinion

PUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 21-1555

JACOB PFALLER, Administrator of the Estate of Danny Harold Pfaller, Plaintiff - Appellee,

v. DR. MARK AMONETTE, in his individual capacity, Defendant - Appellant,

and DR. LAURENCE SHU-CHUNG WANG, in his individual capacity, Defendant.

------------------------------ RIGHTS BEHIND BARS, Amicus Supporting Appellee.

No. 21-1612

JACOB PFALLER, Administrator of the Estate of Danny Harold Pfaller, Plaintiff - Appellee,

v. DR. LAURENCE SHU-CHUNG WANG, in his individual capacity,

Defendant - Appellant,

and DR. MARK AMONETTE, in his individual capacity, Defendant.

------------------------------ RIGHTS BEHIND BARS, Amicus Supporting Appellee.

Appeal from the United States District Court for the Eastern District of Virginia, at Richmond. Robert E. Payne, Senior District Judge. (3:19-cv-00728-REP)

Argued: September 16, 2022 Decided: December 15, 2022

Before WILKINSON, WYNN, and DIAZ, Circuit Judges.

Affirmed in part, reversed in part, and remanded by published opinion. Judge Wynn wrote the opinion, in which Judge Diaz joined. Judge Wilkinson wrote a separate opinion concurring in part and dissenting in part.

ARGUED: Andrew Nathan Ferguson, Erika L. Maley, OFFICE OF THE ATTORNEY GENERAL OF VIRGINIA, Richmond, Virginia, for Appellants. John Michael Shoreman, MCFADDEN & SHOREMAN, Washington, D.C., for Appellee. ON BRIEF: Mark R. Herring, Attorney General, K. Scott Miles, Deputy Attorney General, Laura Maughan, Assistant Attorney General, Michelle S. Kallen, Acting Solicitor General, Brittany M. Jones, Deputy Solicitor General, Laura H. Cahill, Assistant Attorney General, Rohiniyurie Tashima, John Marshall Fellow, OFFICE OF THE ATTORNEY GENERAL OF VIRGINIA, Richmond, Virginia, for Appellant Dr. Amonette. Erin B. Ashwell, Chief Deputy Attorney General, A. Anne Lloyd, Assistant Attorney General, OFFICE OF THE ATTORNEY GENERAL OF VIRGINIA, Richmond, Virginia; Lynne Jones Blain, M. Scott Fisher, Jr., HARMAN CLAYTOR CORRIGAN WELLMAN, Glen Allen, Virginia, for Appellant Dr. Wang. Mario B. Williams, Dallas S. LePierre, HDR LLC, Atlanta,

Georgia, for Appellee. Oren Nimmi, RIGHTS BEHIND BARS, Washington, D.C., for Amicus Rights Behind Bars.

WYNN, Circuit Judge:

Danny Pfaller died from liver cancer while he was a prisoner with the Virginia Department of Corrections (“Department”). His estate sued several prison officials under 42 U.S.C. § 1983 and Virginia law, alleging that they violated the Eighth Amendment and state law by failing to provide Pfaller treatment for his chronic hepatitis C until it was too late.

Defendants in this appeal are Dr. Mark Amonette and Dr. Laurence Shu-Chung Wang. Plaintiff alleges that Dr. Amonette designed treatment guidelines for inmates with hepatitis C that unconstitutionally excluded Pfaller from receiving treatment. Plaintiff also alleges that Dr. Wang failed to follow those guidelines and committed both medical malpractice and Eighth Amendment violations in denying him appropriate treatment. Defendants unsuccessfully moved for summary judgment, alleging that they were protected by qualified immunity and, on Dr. Wang’s part, derivative sovereign immunity.

For the reasons that follow, we reverse the district court’s denial of sovereign immunity to Dr. Wang and denial of qualified immunity to Dr. Amonette but affirm its denial of qualified immunity to Dr. Wang.

I.

Because this case is before us on interlocutory appeal, the following facts are recounted as the district court viewed them, and in the light most favorable to Pfaller. See Hicks v. Ferreyra, 965 F.3d 302, 305 (4th Cir. 2020).

A.

Hepatitis C is a disease caused by a viral infection of the liver. In certain individuals, hepatitis C can persist as an asymptomatic infection for years. In others, the virus can lead to liver inflammation, fibrosis (liver scarring), cirrhosis (liver tissue death), and even terminal liver cancer.

For many years, the only curative treatment for hepatitis C was a course of interferon-based drugs. However, these drugs offered a low cure rate (40 to 50%) and caused major side effects, including life-threatening neuropsychiatric and autoimmune disorders. In 2014, the Food and Drug Administration began approving a suite of new drugs called direct-acting antivirals for treatment of hepatitis C patients. These drugs offered great promise. Not only were they less likely to cause serious side effects, but they also boasted cure rates of 90 to 100%. By 2015, direct-acting antivirals were available for treating hepatitis C patients.

In response to these medical advances, Dr. Amonette, the Department’s chief physician, developed new hepatitis C treatment guidelines (“Guidelines”) for the Department. Under the Guidelines, the Department agreed to refer inmates with hepatitis C to a clinic at Virginia Commonwealth University (“VCU”) based on certain criteria. These criteria sorted inmates into three groups based on APRI and FIB-4 scores that assessed their level of fibrosis (if any). 1 Inmates who scored at the high end of the scale

1

“APRI” stands for “aspartate aminotransferase to platelet ratio.” J.A. 116. It is a noninvasive way to estimate fibrosis, or liver scarring. J.A. 397. “FIB-4” is short for “Fibrosis-4 index,” and is another formula used to assess fibrosis based on a patient’s age,

were to be “automatically referred to VCU for evaluation without any additional testing.” J.A. 116. Inmates who scored in the middle tier were to receive “additional testing to determine whether [they] should be referred for evaluation.” Id. And those who scored at the low end were not to be referred for treatment and instead were to “receive periodic laboratory blood testing and chronic care appointments with a medical provider.” Id. Outside of these criteria, a physician could also refer an inmate to the VCU clinic “if there [were] other findings suggestive of advanced liver disease.” J.A. 303. Once referred, the inmate would receive an antiviral prescription unless there was some other medical reason not to treat them.

Dr. Amonette explains that these Guidelines were designed to ensure that those with the greatest need were treated first. Plaintiff’s expert disputes this, stating that the Guidelines were actually a tool for excluding patients from treatment. The parties agree that when resources are limited, prioritization of patients with the most advanced disease can be a reasonable strategy. But whether the Department’s resources were actually limited is disputed.

B.

Danny Pfaller was an inmate with the Department from 1999 to 2018. As early as 2007, Pfaller tested positive for hepatitis C. Beginning in 2015, Pfaller had his blood drawn

platelet count, and other factors. J.A. 116, 397. Citations to the “J.A.” refer to the parties’ Joint Appendix filed in this appeal.

every six to twelve months to assess his APRI and FIB-4 scores, consistent with the Guidelines. During this time, Dr. Wang served as Pfaller’s primary physician.

Between 2015 and 2018, Dr. Wang twice failed to follow the Guidelines in treating Pfaller. On October 16, 2015, Pfaller tested into the middle tier of the Guidelines criteria and therefore qualified for fibroscan testing to determine the extent of any fibrosis. But Dr. Wang did not refer him. Two years later, following several tests that fell into the lowest tier, Pfaller tested into the middle tier again. But once again, Dr. Wang did not refer him for more testing. Dr. Wang claims both failures were a mistake. He states that he did not refer Pfaller for a fibroscan because he thought the inclusion number for the middle tier was 1.5 on the FIB-4 test, when it was in fact 1.45.

Free access — add to your briefcase to read the full text and ask questions with AI

Jacob Pfaller v. Mark Amonette, 55 F.4th 436 (4th Cir. 2022).

55 F.4th 436 (Jacob Pfaller v. Mark Amonette) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related